Characteristics:
| Type |
Pill |
| Purpose |
Antiparasitic |
| Packaging |
3 pieces
|
| Manufacturer |
Boeringher, France |
Description:
Nextgard Spectra Dog Chews x 3 9mg/2mg chewable tablets for dogs > 1.35 - 3.5 kg
Each chewable tablet contains active substances:
| Nexgard Spectra |
Afoxolaner (mg) |
Milbemycin Oxime (mg) |
| Chewable tablets for dogs 2-3.5 kg |
9.375 |
1.875 |
| Chewable tablets for dogs >3.5-7.5 kg |
18.75 |
3.75 |
| Chewable tablets for dogs >7.5-15 kg |
37.50 |
7.50 |
| Chewable tablets for dogs >15-30 kg |
75.00 |
15.00 |
| Chewable tablets for dogs >30-60 kg |
150.00 |
30.00 |
Red-reddish brown in color, round (tablets for dogs 2-3.5 kg) or rectangular (tablets for dogs >3.5-7.5 kg, tablets for dogs >7.5-15 kg, tablets for dogs >15-30 kg and tablets for dogs >30-60 kg for dogs).
Indications:
For the treatment of flea and tick infestations in dogs when the simultaneous prevention of heartworm disease and/or treatment of gastrointestinal worm infestations is indicated.
Treatment of flea infestations (Ctenocephalides felis and C.canis) in dogs.
Treatment of tick infestations (Dermacentor reticulates, Ixodes ricinus, Rhipicephalus sanguineus) in dogs.
Fleas and ticks must attach to the host and begin feeding in order to be exposed to the active substance.
Treatment of the following species of adult gastrointestinal worms: roundworm (Toxocara canis and Toxascaris leonina), stomach worm (Ancylostoma caninum and Ancylostoma brazilense) and intestinal worm (Trichuris vulpis).
Heartworm Dirofilaria immitis larvae disease prevention by monthly intake.
Contraindications:
Do not use in case of hypersensitivity to the active substance or any of the excipients.
Adverse reactions:
In clinical trials, no serious adverse reactions were attributed to the combination of afoxolaner and milbemycin oxime. The following adverse reactions have been reported infrequently: vomiting, diarrhea, lack of energy, loss of appetite, and itching. These events were generally self-limiting and of short duration.
The frequency of adverse reactions is determined as follows:
Very common (adverse reaction(s) occurred in more than 1 in 10 animals during treatment)
Common (more than 1 in 100, but less than 10)
Uncommon (more than 1 in 1,000 but less than 10)
Rare (more than 1 in 10,000 but less than 10)
Very rare (less than 1 in 10,000 animals, including isolated cases).
If you notice any serious or other side effects not listed in this leaflet, tell your vet
Target species:
dogs.
Administration method:
Used only orally.
Dosage: The veterinary medicinal product is taken according to the following table:
| Dog body weight (kg) |
Acceptable tablet quantity and potency |
| Nexgard Spectra 9mg/2mg |
Nexgard Spectra19 mg/4 mg |
Nexgard Spectra 38mg/8mg |
Nexgard Spectra75 mg/15 mg |
Nexgard Spectra150mg/30mg |
| 2-3.5 |
1 |
|
|
|
|
| >3.5-7.5 |
|
1 |
|
|
|
| >7.5-15 |
|
|
1 |
|
|
| >15-30 |
|
|
|
1 |
|
| >30-60 |
|
|
|
|
1 |
In dogs weighing more than 60 kg, appropriate combinations of chewable tablets are used.
Acceptance rule:
Tablets are chewable and palatable to most dogs. If the dog does not take the tablet directly, it can be given with food.
